Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 20,316 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey S. Flier sold 20,316 shares of the company’s stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $32.24, for a total transaction of $654,987.84. Following the transaction, the director now owns 24,070 shares in the company, valued at $776,016.80. The trade was a 45.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Scholar Rock Stock Up 7.2%

Shares of NASDAQ SRRK opened at $35.81 on Thursday. The firm’s 50-day moving average is $31.92 and its two-hundred day moving average is $35.88. The company has a market capitalization of $3.40 billion, a PE ratio of -14.15 and a beta of 0.28. Scholar Rock Holding Corporation has a 12-month low of $6.76 and a 12-month high of $46.98. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.25 and a quick ratio of 10.25.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.04). During the same quarter in the previous year, the firm earned ($0.59) earnings per share. Equities analysts anticipate that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SRRK has been the topic of several research analyst reports. Wedbush reissued an “outperform” rating and set a $50.00 price target on shares of Scholar Rock in a research note on Wednesday, June 18th. Lifesci Capital upgraded Scholar Rock to a “strong-buy” rating in a research report on Tuesday, June 3rd. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $42.67.

Hedge Funds Weigh In On Scholar Rock

Institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers increased its position in Scholar Rock by 13.2% during the 4th quarter. Rhumbline Advisers now owns 113,261 shares of the company’s stock worth $4,895,000 after purchasing an additional 13,247 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Scholar Rock during the 4th quarter worth about $274,000. New York State Common Retirement Fund boosted its stake in shares of Scholar Rock by 117.5% during the 4th quarter. New York State Common Retirement Fund now owns 22,586 shares of the company’s stock worth $976,000 after purchasing an additional 12,200 shares during the last quarter. Global Retirement Partners LLC grew its holdings in shares of Scholar Rock by 584.7% during the fourth quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock worth $39,000 after buying an additional 766 shares in the last quarter. Finally, Handelsbanken Fonder AB acquired a new position in shares of Scholar Rock in the fourth quarter valued at approximately $942,000. 91.08% of the stock is owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.